Overview
Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis . Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug. Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base . Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system , . A depolarizing neuromuscular-blocking agent causing longstanding nicotinic receptor activation, resulting in spastic paralysis of susceptible nematodes (worms). Pyrantel has shown to be effective after a single dose . In humans, it is administered as pyrantel pamoate ,,,.
Indication
For the treatment of enterobiasis including roundworm (ascariasis), pinworm (enterobius) and hookworm (strongyloides) and hookworm (ancylostoma) in the pyrantel pamoate form . Pyrantel is available in various formulations for humans, dogs, and cats as the pamoate (US Pharmacopeia nomenclature) or embonate (European Pharmacopoeia nomenclature) salt, which contains 34.7% pyrantel base combined with pamoic acid . , . Pyrantel pamoate (embonate) ingested orally is effective for removal and control of ascarid and hookworm infections in puppies and dogs (adult Toxocara canis, Toxascaris leonina, Ancylostoma tubaeforme, An. braziliense, Uncinaria stenocephala), cats (adult Toxocara cati, Toxa. leonina, An. caninum, An. braziliense, U. stenocephala), horses and ponies (adult and immature Parascaris equorum, adult Strongylus vulgaris, S. edentatus, S. equinus, Cyathostomes (Triodontophorus spp., Cyathostomum spp., Cylicodontophorus spp., Cylicocyclus spp., Cylicostephanus spp., Poteriostomum spp.), Oxyuris equi, Anoplocephala perfoliata), swine (adult Ascaris suum, Oesophagostomum dentatum), and humans (adult A. lumbricoides, Enterobius vermicularis, An. duodenale, Necator americanus) .
Associated Conditions
- Enterobiasis
- Helminthic infection
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2017/09/11 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Zoetis Inc. | 54771-2684 | ORAL | 25 mg in 1 1 | 5/23/2025 | |
| Zoetis Inc. | 54771-2670 | ORAL | 200 mg in 1 1 | 5/23/2025 | |
| Zoetis Inc. | 54771-2667 | ORAL | 12.5 mg in 1 1 | 5/23/2025 | |
| Zoetis Inc. | 54771-2671 | ORAL | 300 mg in 1 1 | 5/23/2025 | |
| Pharmadel LLC | 55758-441 | ORAL | 180 mg in 1 1 | 6/18/2025 | |
| Zoetis Inc. | 54771-2668 | ORAL | 50 mg in 1 1 | 5/23/2025 | |
| GiarCidia LLC | 86218-994 | ORAL | 28.54 mg in 1 mL | 6/3/2025 | |
| Zoetis Inc. | 54771-2669 | ORAL | 100 mg in 1 1 | 5/23/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Pyrantel Pamoate Granules | 国药准字H23020321 | 化学药品 | 颗粒剂 | 6/22/2020 | |
| Pyrantel Pamoate Granules | 国药准字H11020369 | 化学药品 | 颗粒剂 | 12/11/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H52020003 | 化学药品 | 片剂 | 7/16/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H11021646 | 化学药品 | 片剂 | 12/23/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H65020125 | 化学药品 | 片剂 | 7/20/2022 | |
| Pyrantel Pamoate Tablets | 国药准字H35020262 | 化学药品 | 片剂 | 9/3/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H44023030 | 化学药品 | 片剂 | 3/4/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H42020369 | 化学药品 | 片剂 | 9/17/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H13021962 | 化学药品 | 片剂 | 10/13/2020 | |
| Pyrantel Pamoate Tablets | 国药准字H41023272 | 化学药品 | 片剂 | 6/12/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.